Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept study of LTX-109 in hidradenitis suppurativa
2020-000042-34Phase 2Completed
- Start
- Jan 2020
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of voxvoganan in hidradenitis suppurativa (HS). Primary endpoint: Patient-reported improvement. Started Jan 2020; status: completed.
02
Drugs
voxvoganan
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2020-000042-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000042-34.